RecruitingNCT02061306

Celiac Disease Genomic Environmental Microbiome and Metabolomic Study

Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) Study


Sponsor

Massachusetts General Hospital

Enrollment

500 participants

Start Date

Mar 1, 2014

Study Type

OBSERVATIONAL

Conditions

Summary

Celiac disease (CD) is a complex disease caused by eating gluten, a protein contained in wheat, rye, and barley. It is well known that many factors contribute to the development of CD, including the genes that you have and the foods that you eat. In the CDGEMM study, we will consider as many of these factors as possible and study how they each contribute to disease development. If the investigators find that any one factor, or combination of factors, increases the risk of developing CD, we will be able to apply this information and help prevent or detect disease in high-risk children in the future.


Eligibility

Max Age: 6 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with celiac disease. The study is currently recruiting participants at 2 locations. People eligible for this study include up to age 6 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

MassGeneral Hospital for Children

Boston, Massachusetts, United States

University of Roma La Sapienza

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02061306


Related Trials